Evidence map›Paper›PMID 11991960›Full record

ArticleJournal of virology2002

Envelope glycoprotein incorporation, not shedding of surface envelope glycoprotein (gp120/SU), Is the primary determinant of SU content of purified human immunodeficiency virus type 1 and simian immunodeficiency virus.

Elena Chertova, Julian W Bess, Bruce J Crise, Raymond C Sowder II, Terra M Schaden, Joanne M Hilburn, James A Hoxie, Raoul E Benveniste, Jeffrey D Lifson, Louis E Henderson and 1 more

Open access · greenAbstract read
In one paragraph

Article in Journal of virology, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 187 papers.

0numbers the graph read from it
0cells of the map it votes in
187citing papers in PubMed
5.1field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

187 citing papers in PubMed, 284 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Activation of CXCR3Journal of virology · 2025
    Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. mRNA-based HIV-1 vaccines.Clinical microbiology reviews · 2024
    Review
  18. Article
  19. Article
  20. Article

127 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Elena ChertovaAIDS Vaccine Program, SAIC Frederick, Maryland 21702-1201, USA. chertova@mail.ncicrf.gov
Julian W Bess
Bruce J Crise
Raymond C Sowder II
Terra M Schaden
Joanne M Hilburn
James A Hoxie
Raoul E Benveniste
Jeffrey D Lifson
Louis E Henderson
Larry O Arthur
Science Applications International Corporation (United States) · USFrederick National Laboratory for Cancer Research · USUniversity of Pennsylvania · US

Funding

NCI NIH HHS N01 CO012400NCI NIH HHS N01-CO-12400
6 · The paper itself

Abstract

Human immunodeficiency virus type 1 (HIV-1) and simian immunodeficiency virus (SIV) particles typically contain small amounts of the surface envelope protein (SU), and this is widely believed to be due to shedding of SU from mature virions. We purified proteins from HIV-1 and SIV isolates using procedures which allow quantitative measurements of viral protein content and determination of the ratios of gag- and env-encoded proteins in virions. All of the HIV-1 and most of the SIV isolates examined contained low levels of envelope proteins, with Gag:Env ratios of approximately 60:1. Based on an estimate of 1,200 to 2,500 Gag molecules per virion, this corresponds to an average of between 21 and 42 SU molecules, or between 7 and 14 trimers, per particle. In contrast, some SIV isolates contained levels of SU at least 10-fold greater than SU from HIV-1 isolates. Quantification of relative amounts of SU and transmembrane envelope protein (TM) provides a means to assess the impact of SU shedding on virion SU content, since such shedding would be expected to result in a molar excess of TM over SU on virions that had shed SU. With one exception, viruses with sufficient SU and TM to allow quantification were found to have approximately equivalent molar amounts of SU and TM. The quantity of SU associated with virions and the SU:TM ratios were not significantly changed during multiple freeze-thaw cycles or purification through sucrose gradients. Exposure of purified HIV-1 and SIV to temperatures of 55 degrees C or greater for 1 h resulted in loss of most of the SU from the virus but retention of TM. Incubation of purified virus with soluble CD4 at 37 degrees C resulted in no appreciable loss of SU from either SIV or HIV-1. These results indicate that the association of SU and TM on the purified virions studied is quite stable. These findings suggest that incorporation of SU-TM complexes into the viral membrane may be the primary factor determining the quantity of SU associated with SIV and HIV-1 virions, rather than shedding of SU from mature virions.

Indexed as

AnimalsCD4 AntigensCHO CellsCricetinaeFreezingGene Products, envGene Products, gagHeatingHIV-1HIV Envelope Protein gp120HIV Envelope Protein gp41HumansMembrane GlycoproteinsRetroviridae ProteinsSimian Immunodeficiency VirusViral Envelope ProteinsCD4 AntigensGene Products, envGene Products, gaggp120 protein, Simian immunodeficiency virusHIV Envelope Protein gp120HIV Envelope Protein gp41Membrane GlycoproteinsRetroviridae ProteinsSIV envelope protein gp41Viral Envelope Proteins

Identifiers

PMID11991960
PMCPMC137021
OpenAlexW2004361534

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.